Melanoma Adjuvant Treatment: Current Insight and Clinical Features.
D'Aniello C, Perri F, Scarpati GDV, Pepa CD, Pisconti S, Montesarchio V, Wernert N, Zarone MR, Caraglia M, Facchini G, Berretta M, Cavaliere C.
D'Aniello C, et al.
Curr Cancer Drug Targets. 2018;18(5):442-456. doi: 10.2174/1568009617666170208163714.
Curr Cancer Drug Targets. 2018.
PMID: 28183255
Review.
Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. ...Ipilimumab represents a possible breakthrough in this setting, considering the positive results of the EORTC 18701 trials in terms of dis …
Melanoma represents 2-3% of all cancers, 95% of them arise from skin, while only 5% are non-cutaneous melanoma. …